White Papers
July 2, 2024
This paper explores the costs of setting up and operationalizing a supply chain in Europe for a new biopharma therapy. Specifically, it outlines the key cost drivers, along with the various “levers” that decision makers can use to affect those costs.
White Papers
March 22, 2024
Interest in rare disease (RD) therapies continues to rise, with many established companies incorporating RD therapies into their portfolios for the first time. This paper:
White Papers
September 27, 2023
A combination of economic and regulatory factors are driving up the cost and complexity of biopharma supply chains in the EU. This paper explores those factors and outlines both “upstream” and “downstream” strategies that pharma and biotech companies can use to better manage cost, complexity, and risk.
White Papers
October 27, 2022
Advanced Therapy Medicinal Products (ATMPs), also known as cell and gene therapies, are becoming increasingly common. However, they’re far more complex than “traditional” biotech products, with sophisticated requirements throughout their supply chains.
On October 20, 2022, AIM conducted a webinar on how companies can orchestrate successful supply chains for ATMPs. This paper provides a written summary of the webinar discussion.
For a time, webinar registrants can also access a recorded copy of the webinar here.
White Papers
October 30, 2021
On 27 October 2021, AIM hosted a webinar panel discussion that addressed the key supply chain aspects associated with launching a new pharmaceutical or biotech therapy in Europe.
Our panel of experts included:
The panelists covered supply chain key success factors, best practices, and common pitfalls and mistakes. They also discussed key licensing and legal requirements, as well as the main steps involved in designing and implementing a life science supply chain in Europe. This paper provides a written summary of the webinar.
